|
1
|
Spiro RH, Huvos AG and Strong EW: Adenoid
cystic carcinoma of salivary origin. A clinicopathologic study of
242 cases. Am J Surg. 128:512–520. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chae YK, Chung SY, Davis AA, Carneiro BA,
Chandra S, Kaplan J, Kalyan A and Giles FJ: Adenoid cystic
carcinoma: Current therapy and potential therapeutic advances based
on genomic profiling. Oncotarget. 6:37117–37134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doescher J, Weissinger SE, Schönsteiner
SS, Lisson C, Bullinger L, Barth TF, Leithäuser F, Mueller-Richter
U, Laban S, Hoffmann TK, et al: Clinical utility of a protein-based
oncopanel in patients with end-stage head and neck cancer.
Immunotherapy. 11:1193–1203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wysocki PT, Izumchenko E, Meir J, Ha PK,
Sidransky D and Brait M: Adenoid cystic carcinoma: Emerging role of
translocations and gene fusions. Oncotarget. 7:66239–66254. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pham T, Pereira L, Roth S, Galletta L,
Link E, Akhurst T, Solomon B, Michael M, Darcy P, Sampurno S, et
al: First-in-human phase I clinical trial of a combined immune
modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in
patients with advanced solid cancer including colorectal or adenoid
cystic carcinoma: The MYPHISMO study protocol (NCT03287427).
Contemp Clin Trials Commun. 16:1004092019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zupancic M, Näsman A, Friesland S and
Dalianis T: Adenoid cystic carcinoma, clinical presentation,
current treatment and approaches towards novel therapies.
Anticancer Res. 44:1325–1334. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stenman G, Licitra L, Said-Al-Naief N, van
Zante A and Yarbrough W: Adenoid cystic carcinoma. WHO
Classification of Head and Neck Tumours. World Health Organization
Classification of Tumours. El-Naggar AK, Chan JKC, Grandis JR,
Takata T and Slootweg PJ: 4th edition. Vol 9. International Agency
for Research on Cancer; Lyon: pp. 164–165. 2017
|
|
8
|
Ueda K, Murase T, Nagao T, Kusafuka K,
Urano M, Yamamoto H, Nakaguro M, Taguchi KI, Masaki A, Hirai H, et
al: Central pathology review of salivary gland adenoid cystic
carcinoma. Head Neck. 42:1721–1727. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grünmüller L, Thierauf J, Weissinger SE,
Bergmann C, Bankfalvi A, Veit J, Hoffmann TK, Möller P and Lennerz
JK: Biopanel identifies expression status of targetable proteins in
sinonasal melanoma. Per Med. 13:291–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu Z, Eils R and Schlesner M: Complex
heatmaps reveal patterns and correlations in multidimensional
genomic data. Bioinformatics. 32:2847–2849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Peng B and Chen X: Expressions of
nuclear factor kappaB, inducible nitric oxide synthase, and
vascular endothelial growth factor in adenoid cystic carcinoma of
salivary glands: correlations with the angiogenesis and clinical
outcome. Clin Cancer Res. 11:7334–7343. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Locati LD, Cavalieri S, Bergamini C,
Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini
E, Quattrone P, et al: Phase II trial with axitinib in recurrent
and/or metastatic salivary gland cancers of the upper aerodigestive
tract. Head Neck. 41:3670–3676. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tchekmedyian V, Sherman EJ, Dunn L, Tran
C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister
DG and Ho AL: Phase II study of lenvatinib in patients with
progressive, recurrent or metastatic adenoid cystic carcinoma. J
Clin Oncol. 37:1529–1537. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu G, Zhang L, Dou S, Li R, Li J, Ye L,
Jiang W, Dong M, Ruan M, Yang W and Zhang C: Apatinib in patients
with recurrent or metastatic adenoid cystic carcinoma of the head
and neck: A single-arm, phase II prospective study. Ther Adv Med
Oncol. 13:175883592110136262021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pfeffer MR, Talmi Y, Catane R, Symon Z,
Yosepovitch A and Levitt M: A phase II study of Imatinib for
advanced adenoid cystic carcinoma of head and neck salivary glands.
Oral Oncol. 43:33–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hotte SJ, Winquist EW, Lamont E, MacKenzie
M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A and Siu LL: Imatinib
mesylate in patients with adenoid cystic cancers of the salivary
glands expressing c-kit: A princess margaret hospital phase II
consortium study. J Clin Oncol. 23:585–590. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edwards PC, Bhuiya T and Kelsch RD: C-kit
expression in the salivary gland neoplasms adenoid cystic
carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic
adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
95:586–593. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vered M, Braunstein E and Buchner A:
Immunohistochemical study of epidermal growth factor receptor in
adenoid cystic carcinoma of salivary gland origin. Head Neck.
24:632–636. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Locati LD, Bossi P, Perrone F, Potepan P,
Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, et
al: Cetuximab in recurrent and/or metastatic salivary gland
carcinomas: A phase II study. Oral Oncol. 45:574–578. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jakob JA, Kies MS, Glisson BS, Kupferman
ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM and
Blumenschein GR Jr: Phase II study of gefitinib in patients with
advanced salivary gland cancers. Head Neck. 37:644–649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi
SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Haque S, et al:
A phase II study of axitinib (AG-013736) in patients with incurable
adenoid cystic carcinoma. Ann Oncol. 27:1902–1908. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laurie SA, Ho AL, Fury MG, Sherman E and
Pfister DG: Systemic therapy in the management of metastatic or
locally recurrent adenoid cystic carcinoma of the salivary glands:
A systematic review. Lancet Oncol. 12:815–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Locati LD, Galbiati D, Calareso G, Alfieri
S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E,
Resteghini C, et al: Patients with adenoid cystic carcinomas of the
salivary glands treated with lenvatinib: Activity and quality of
life. Cancer. 126:1888–1894. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Geiger JL, Ismaila N, Beadle B, Caudell
JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau
HY, et al: Management of salivary gland malignancy: ASCO guideline.
J Clin Oncol. 39:1909–1941. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Witzleben A, Müller-Richter U, Maurus
K, Brändlein S, Theodoraki MN, Brunner C, Laban S, Lennerz J,
Möller P, Hoffmann TK, et al: Protein-based oncopanel as addition
to target sequencing in head and neck squamous cell carcinoma to
individualize treatment decisions. Int J Mol Sci. 23:158352022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi H, Tada Y, Saotome T, Akazawa K,
Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, et
al: Phase II trial of trastuzumab and docetaxel in patients with
human epidermal growth factor receptor 2-positive salivary duct
carcinoma. J Clin Oncol. 37:125–134. 2019. View Article : Google Scholar : PubMed/NCBI
|